Zimmer Biomet's RibFix Advantage System Receives First CE Mark for Intrathoracic Rib Fixation
Key Insights
Zimmer Biomet has received CE Mark certification for its RibFix Advantage Fixation System (search), marking the first CE Mark approval for an intrathoracic rib fixation system.
The system enables thoracoscopic fixation of rib fractures (search) through a minimally invasive approach, potentially reducing soft tissue disruption compared to traditional open reduction internal fixation.
With this certification, Zimmer Biomet will expand availability of the RibFix Advantage Fixation System (search) to the European Economic Area and other markets that recognize the CE Mark.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, announced today that its RibFix Advantage Fixation System (search) has received CE Mark certification, representing the first CE Mark approval for an intrathoracic rib fixation system.
The innovative system is designed for thoracoscopic fixation, stabilization, and fusion of rib fractures (search), offering surgeons a minimally invasive alternative to traditional open reduction internal fixation procedures. This approach has the potential to significantly reduce soft tissue disruption during surgical intervention.
"Following the success of RibFix Advantage Fixation System (search) in the United States and other markets, we are excited to introduce it in CE Mark markets and support our customers with solutions that meet their evolving surgical needs," said Wilfred van Zuilen, Zimmer Biomet Group President, EMEA. "We remain dedicated to advancing MedTech and delivering high-quality solutions for healthcare professionals and their patients worldwide."
Advanced Design Features
A key innovation of the RibFix Advantage system is its specialized bridge component that adapts to the anatomy of the rib during the tightening process. This feature enables auto-contouring to reduce the fracture, providing a more anatomically appropriate fixation compared to conventional methods.
The system represents a significant advancement in rib fracture management, combining innovative technology with surgical techniques that aim to improve patient outcomes while potentially reducing surgical complications.
European Market Expansion
With this CE Mark certification, Zimmer Biomet will now make the RibFix Advantage Fixation System (search) available throughout the European Economic Area (EEA) and other global markets that recognize CE Mark certification as a standard for medical device approval.
This expansion builds upon the system's existing success in the United States and other international markets, further strengthening Zimmer Biomet's thoracic portfolio and global market presence.
Clinical Implications
Rib fractures (search) are common thoracic injuries that can lead to significant morbidity and mortality, particularly in elderly patients or those with multiple fractures. Traditional management approaches have included conservative treatment or open surgical procedures, each with their own limitations.
The RibFix Advantage system's minimally invasive approach may offer several potential benefits, including reduced surgical trauma, decreased post-operative pain, and potentially shorter hospital stays. By enabling thoracoscopic fixation, the system allows surgeons to address rib fractures (search) while minimizing the additional tissue damage often associated with conventional open procedures.
About Zimmer Biomet
Zimmer Biomet has established itself as a global medical technology leader with over 90 years of experience in the industry. The company maintains operations in more than 25 countries and distributes its products across more than 100 countries worldwide.
The company's comprehensive portfolio is designed to maximize mobility and improve health through innovative products and integrated digital and robotic technologies that leverage data analytics and artificial intelligence. This CE Mark certification further demonstrates Zimmer Biomet's commitment to advancing medical technology and addressing unmet clinical needs in thoracic surgery.